RxDoctor Payments Data

Sunil Pauwaa, MD

Advanced Heart Failure and Transplant Cardiology · Oak Lawn, ILNPI 1710125109

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $38,325 of the $61,942 with a category attached, or 61.9%. 32 manufacturers reported payments, led by AstraZeneca at 28.0% of the total. Reporting peaked in 2021 at $22,121 and has fallen 92.8% since, to $1,595 in 2025.

$61,942in general payments, 2019–2025

Across 387 payments — averaging $160.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$17K
  • Novartis$16K
  • Abbott$10K
  • Pfizer$9K
  • Terumo Medical Corporation$6K
  • Novo Nordisk$660
  • plus $4K from 26 others
$16,071in research payments, 2019–2025

Across 9 payments — averaging $1785.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$16K

What the payments were for

  • Consulting fees$9,82516%
  • Speaking & faculty fees$38,32562%
  • Travel & lodging$1,9063%
  • Food & beverage$11,85719%
  • Education$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,942 in reported general payments places this provider in the 80th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.

See all advanced heart failure and transplant cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$132,320
Medicare patients
415
Services billed
1,653

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Orenitram ErTreprostinil Diolamine99$1,380,088
VyndamaxTafamidis43$1,030,396
AdempasRiociguat55$753,844
OpsumitMacitentan49$651,052
Tyvaso DpiTreprostinil24$561,498
WinrevairSotatercept-Csrk30$423,624
UptraviSelexipag13$354,183
EntrestoSacubitril/Valsartan206$273,588
RemodulinTreprostinil Sodium24$177,734
EliquisApixaban130$126,730
JardianceEmpagliflozin84$108,015
Ambrisentan12$92,991
FarxigaDapagliflozin Propanediol65$58,643
Tadalafil27$19,588
XareltoRivaroxaban21$17,792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$8,828$1,157,126173 claims
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$252$1,005,23562 claims
BayerAdempas$18$753,84455 claims
NovartisEntresto$15,755$273,588206 claims
United Therapeutics CorporationRemodulin$520$177,73424 claims
Boehringer IngelheimJardiance$220$108,01584 claims
AstraZenecaFarxiga$17,338$58,64365 claims
Johnson & JohnsonXarelto$359$17,79221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 56 advanced heart failure and transplant cardiology providers in Illinois.

Other advanced heart failure and transplant cardiology in Oak Lawn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →